Australia Announces A “Fairer” Orphan Drugs Program, With New Eligibility And Validity Criteria
Executive Summary
New orphan drug designations under Australia’s reformed program will lapse after six months, although there is a 12-month transitional period for existing designations.
You may also be interested in...
Australian Orphan Fee Waivers To Expire As Transition Period Ends
The transition period for Australia’s new orphan drug program is coming to an end, and sponsors may need to take action if they want to keep their orphan status - and fee waivers - beyond the end of June.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.